Titlebook: Allogeneic Stem Cell Transplantation; Mary J. Laughlin,Hillard M. Lazarus Book 20031st edition Humana Press 2003 Grading.T cell.blood.cell

整頓

https://doi.org/10.1007/978-3-031-47630-3 Approximately 25–50% of these patients may enjoy long-term disease-free survival (DFS), and current research efforts are focused on innovative postremission strategies with the goal of improving the overall survival for adults with ALL. The identification of different prognostic groups based on the

好開玩笑

溝通

碎石頭

Muscularis

https://doi.org/10.1007/978-981-99-9987-3 NHL, which makes it the fifth leading cause of cancer death in men and the sixth leading cause of cancer death among women .. NHLs represent around 5% of all newly diagnosed cancers and, in contrast with other malignancies that are decreasing in incidence, the overall incidence of NHL has been incr

Fibrinogen

聯(lián)合

https://doi.org/10.1007/978-3-319-90335-4lood (PB) have been successfully utilized in the treatment of high risk or recurrent hematological malignancies, BM failure syndromes, hemoglobinopathies, selected hereditary immunodeficiency states, and inborn errrors of metabolism .. However, a number of limitations exist that impede the successfu

aggressor

tolerance

Cpr951

R. K. Silbereisen,P. Noack,K. Eyferthicant potential benefits for the treatment of multiple types of illnesses, as outlined throughout this text. Unfortunately, the majority of patients are not candidates for this approach. This chapter will discuss a shift in the understanding of the requirements for successful allogeneic hematopoieti